| AIS | Adenocarcinoma in situ |
| ALTS | ASCUS/LSIL Triage Study |
| AGC | Atypical galndular cells |
| ASC | Atypical squamous cells |
| ASC | American Society of Cytology |
| ASCP | American Society of Clinical Pathologists |
| ASC-H | Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion |
| ASC-US | Atypical squamous cells of undetermined significance |
| CAP | College of American Pathologists |
| CIS | Carcinoma in situ |
| CIN | Cervical intraepithelial neoplasia |
| CP | Conventional preparation |
| DES | Diethylstilbestrol |
| HSIL | High-grade squamous intraepitheial lesion |
| FIGO | International Federation of Gynecology and Obstetrics |
| HPV | Human Papilloma Virus |
| IARC | International Agency for Research on Cancer |
| ISH | In situ Hybridization |
| IUD | Intrauterine device |
| LBP | Liquid-based preparation |
| LEEP | Loop electrosurgical |
| LMP | Last menstrual period (in days) |
| LUS | Lower uterine segment |
| LSIL | Low-grade squamous intraepithelial lesion |
| N/C | Nuclear/cytoplasmic ratio |
| NCI | National Cancer Institute (Bethesda USA) |
| NILM | Negative for intraepithelial lesion or malignancy |
| NOS | Not otherwise specified |
| PCR | Polymerase Chain Reaction |
| RB | RetinoBlastoma (gene) |
| RCH | Reserve cell hyperplasia |
| SCUC | Small cell undifferentiated carcinoma |
| SCC | Squamous cell carcinoma |
| SIL | Squamous intraepithelial lesion |
| TBS | The Bethesda System |
| TCC | Transitional cell carcinoma (urothelial) |
| TNM | Tumour Node Metastasis |
| T zone | Transformation zone |
| UICC | International Union Against Cancer |
| WHO | World Health Organization |